sNDA application submitted for agitation drug
Biopharmaceutical company BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for agitation treatment Igalmi. Igalmi (dexmedetomidine) is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I and II in adults. In April 2022, Igalmi was… Read More
